Alerta

METHODS FOR THE TREATMENT OF MULTIPLE MYELOMA

Resumen de: US20250177520A1

Methods of treating multiple myeloma by administering a bispecific antibody that binds to CD3 and BCMA to a patient in need are provided.

USE OF A MEDICAMENT SIMULTANEOUSLY TARGETING THE TYROSINE KINASE ACTIVITY AND GEF ACTIVITY OF EGFR

Resumen de: EP4817602A1

The present invention provides an EGFR inhibitor for use in the preparation of a medicament for treating diseases mediated by guanosine exchange factor (GEF) activity or co-mediated by guanosine nucleotide exchange factor (GEF) activity and EGFR tyrosine kinase activity, wherein the diseases are selected from the group consisting of: lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, prostate cancer, melanoma, leukemia, and glioblastoma. Specifically, the present invention has discovered that in addition to its conventional tyrosine kinase activity, EGFR also possesses a GEF function that promotes the activation of Ras homologous protein (Rheb), this function is independent of its tyrosine kinase activity and relies critically on the glutamate residue at position 804 on the EGFR molecule. The Rheb-GEF activity of EGFR induces allosteric activation of mammalian target of rapamycin complex 1 (mTORC1), ultimately promoting tumor growth.

METHODS, BIOMARKERS, AND KITS FOR DETECTION OF MULTIPLE MYELOMA

Resumen de: EP4818333A1

The present invention relates to an in vitro method for detecting multiple myeloma in a subject. The invention further provides the use of chemokine receptor CXCR3 (CXCR3) as a biomarker for diagnosing, prognosing, and/or treatment monitoring of multiple myeloma in a subject. The invention further provides a kit for the detection of multiple myeloma in a subject.

Chimeric protein

Resumen de: GB2705211A

A chimeric protein comprising a first peptide linked to a second peptide. The second peptide includes an epitope. The second peptide is formed from C-terminal and N-terminal segments of a target peptide comprising the epitope. The relative positions of the C-terminal segment and the N-terminal segment are transposed in the second peptide relative to the target peptide. The epitope can be formed from both first and second segments of the second peptide. The second peptide can be IL-31, IL-6, IL-11, ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin 1 (CT-1), cardiotrophin-like cytokine (CLC), or IL-27. The second peptide can be human or canine IL-31. The first peptide can be a bacterial colicin, bacterial ribonuclease, spycatcher protein, ColE7, or Barnase. A further aspect is a virus-like particle comprising the chimeric protein. A further aspect is a polynucleotide capable of hybridizing the polynucleotide. A further aspect is a method of producing the chimeric protein wherein the target peptide is split at a division site without disrupting formation of secondary structure elements. A further aspect is an immunogenic composition comprising the chimeric protein for use in treating atopic dermatitis, cancer, inflammatory, neurodegenerative, metabolic, cardiovascular, renal, gastrointestinal, respiratory, autoimmune diseases. Figure 6

BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA

Nº publicación: NL4002684A 06/10/2026

Solicitante:

LEGEND BIOTECH USA INC [US]
JANSSEN BIOTECH INC [US]
LEGEND BIOTECH USA INC.
JANSSEN BIOTECH, INC.

Resumen de: NL4002684A

0001 ABSTRACT Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an 5 epitope of BCMA are administered to the subject.